Dataset Information

LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer.

ABSTRACT: Therapeutic harnessing of adaptive immunity via checkpoint inhibition has transformed the treatment of many cancers. Despite unprecedented long-term responses, most patients do not respond to these therapies. Immunotherapy non-responders often harbor high levels of circulating myeloid-derived suppressor cells (MDSCs)-an immunosuppressive innate cell population. Through genetic and pharmacological approaches, we uncovered a pathway governing MDSC abundance in multiple cancer types. Therapeutic liver-X nuclear receptor (LXR) agonism reduced MDSC abundance in murine models and in patients treated in a first-in-human dose escalation phase 1 trial. MDSC depletion was associated with activation of cytotoxic T lymphocyte (CTL) responses in mice and patients. The LXR transcriptional target ApoE mediated these effects in mice, where LXR/ApoE activation therapy elicited robust anti-tumor responses and also enhanced T cell activation during various immune-based therapies. We implicate the LXR/ApoE axis in the regulation of innate immune suppression and as a target for enhancing the efficacy of cancer immunotherapy in patients.

SUBMITTER: Tavazoie MF

PROVIDER: S-EPMC5846344 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer.

Tavazoie Masoud F MF Pollack Ilana I Tanqueco Raissa R Ostendorf Benjamin N BN Reis Bernardo S BS Gonsalves Foster C FC Kurth Isabel I Andreu-Agullo Celia C Derbyshire Mark L ML Posada Jessica J Takeda Shugaku S Tafreshian Kimia N KN Rowinsky Eric E Szarek Michael M Waltzman Roger J RJ Mcmillan Elizabeth A EA Zhao Connie C Mita Monica M Mita Alain A Chmielowski Bartosz B Postow Michael A MA Ribas Antoni A Mucida Daniel D Tavazoie Sohail F SF

Cell 20180111 4

Therapeutic harnessing of adaptive immunity via checkpoint inhibition has transformed the treatment of many cancers. Despite unprecedented long-term responses, most patients do not respond to these therapies. Immunotherapy non-responders often harbor high levels of circulating myeloid-derived suppressor cells (MDSCs)-an immunosuppressive innate cell population. Through genetic and pharmacological approaches, we uncovered a pathway governing MDSC abundance in multiple cancer types. Therapeutic li ...[more]

PMID: 29336888

Similar Datasets

Project description:Gammaherpesviruses are ubiquitous viruses that establish lifelong infections. Importantly, these viruses are associated with numerous cancers and lymphoproliferative diseases. While risk factors for developing gammaherpesvirus-driven cancers are poorly understood, it is clear that elevated viral reactivation from latency often precedes oncogenesis. Here, we demonstrate that the liver X receptor alpha isoform (LXR?) restricts gammaherpesvirus reactivation in an anatomic-site-specific manner. We have previously demonstrated that deficiency of both LXR isoforms (? and ?) leads to an increase in fatty acid and cholesterol synthesis in primary macrophage cultures, with a corresponding increase in gammaherpesvirus replication. Interestingly, expression of fatty acid synthesis genes was not derepressed in LXR?-deficient hosts, indicating that the antiviral effects of LXR? are independent of lipogenesis. Additionally, the critical host defenses against gammaherpesvirus reactivation, virus-specific CD8+ T cells and interferon (IFN) signaling, remained intact in the absence of LXR?. Remarkably, using a murine gammaherpesvirus 68 (MHV68) reporter virus, we discovered that LXR? expression dictates the cellular tropism of MHV68 in the peritoneal cavity. Specifically, LXR?-/- mice exhibit reduced latency within the peritoneal B cell compartment and elevated latency within F4/80+ cells. Thus, LXR? restricts gammaherpesvirus reactivation through a novel mechanism that is independent of the known CD8+ T cell-based antiviral responses or changes in lipid synthesis and likely involves changes in the tropism of MHV68 in the peritoneal cavity.IMPORTANCE Liver X receptors (LXRs) are nuclear receptors that mediate cholesterol and fatty acid homeostasis. Importantly, as ligand-activated transcription factors, LXRs represent potential targets for the treatment of hypercholesterolemia and atherosclerosis. Here, we demonstrate that LXR?, one of the two LXR isoforms, restricts reactivation of latent gammaherpesvirus from peritoneal cells. As gammaherpesviruses are ubiquitous oncogenic agents, LXRs may represent a targetable host factor for the treatment of poorly controlled gammaherpesvirus infection and associated lymphomagenesis.

Dataset Information

LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer.

Publications

LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets